DURVALUMAB for Lung neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 641 adverse event reports in the FDA FAERS database where DURVALUMAB was used for Lung neoplasm malignant.
Most Reported Side Effects for DURVALUMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 2,817 | 16.4% | 2,816 | 98 |
| Malignant neoplasm progression | 1,330 | 7.8% | 343 | 166 |
| Pneumonitis | 827 | 4.8% | 221 | 333 |
| Radiation pneumonitis | 786 | 4.6% | 112 | 343 |
| Pyrexia | 573 | 3.3% | 79 | 372 |
| Diarrhoea | 530 | 3.1% | 99 | 267 |
| Pneumonia | 453 | 2.6% | 169 | 300 |
| Dyspnoea | 444 | 2.6% | 113 | 215 |
| Interstitial lung disease | 430 | 2.5% | 144 | 220 |
| Off label use | 395 | 2.3% | 70 | 102 |
| Fatigue | 367 | 2.1% | 57 | 102 |
| Rash | 359 | 2.1% | 43 | 94 |
| Neutrophil count decreased | 343 | 2.0% | 49 | 76 |
| Asthenia | 326 | 1.9% | 104 | 121 |
| Colitis | 319 | 1.9% | 73 | 164 |
Other Indications for DURVALUMAB
Non-small cell lung cancer (3,396)
Hepatocellular carcinoma (1,255)
Small cell lung cancer (1,063)
Bile duct cancer (972)
Non-small cell lung cancer stage iii (840)
Small cell lung cancer extensive stage (660)
Pancreatic carcinoma (584)
Cholangiocarcinoma (444)
Neoplasm malignant (253)
Pancreatic carcinoma metastatic (184)
Other Drugs Used for Lung neoplasm malignant
ERLOTINIB (9,207)
OSIMERTINIB (4,754)
NIVOLUMAB (4,197)
PEMBROLIZUMAB (3,575)
CARBOPLATIN (3,487)
ALECTINIB (2,932)
PEMETREXED (2,422)
CRIZOTINIB (1,949)
BEVACIZUMAB (1,810)
PACLITAXEL (1,747)